GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quantum BioPharma Ltd (XCNQ:QNTM) » Definitions » EV-to-EBITDA

Quantum BioPharma (XCNQ:QNTM) EV-to-EBITDA : -2.64 (As of Jul. 09, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Quantum BioPharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Quantum BioPharma's enterprise value is C$76.82 Mil. Quantum BioPharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was C$-29.10 Mil. Therefore, Quantum BioPharma's EV-to-EBITDA for today is -2.64.

The historical rank and industry rank for Quantum BioPharma's EV-to-EBITDA or its related term are showing as below:

XCNQ:QNTM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -237.84   Med: -0.16   Max: 15834.96
Current: -2.64

During the past 10 years, the highest EV-to-EBITDA of Quantum BioPharma was 15834.96. The lowest was -237.84. And the median was -0.16.

XCNQ:QNTM's EV-to-EBITDA is ranked worse than
100% of 469 companies
in the Biotechnology industry
Industry Median: 9.99 vs XCNQ:QNTM: -2.64

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-07-09), Quantum BioPharma's stock price is C$23.85. Quantum BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was C$-21.164. Therefore, Quantum BioPharma's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Quantum BioPharma EV-to-EBITDA Historical Data

The historical data trend for Quantum BioPharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantum BioPharma EV-to-EBITDA Chart

Quantum BioPharma Annual Data
Trend Aug15 Aug16 Aug17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.53 -0.23 -0.59 -2.02 -0.07

Quantum BioPharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.56 -0.45 - -0.07 -0.87

Competitive Comparison of Quantum BioPharma's EV-to-EBITDA

For the Biotechnology subindustry, Quantum BioPharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quantum BioPharma's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quantum BioPharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Quantum BioPharma's EV-to-EBITDA falls into.


;
;

Quantum BioPharma EV-to-EBITDA Calculation

Quantum BioPharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=76.818/-29.103
=-2.64

Quantum BioPharma's current Enterprise Value is C$76.82 Mil.
Quantum BioPharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-29.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quantum BioPharma  (XCNQ:QNTM) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Quantum BioPharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=23.85/-21.164
=At Loss

Quantum BioPharma's share price for today is C$23.85.
Quantum BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-21.164.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Quantum BioPharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Quantum BioPharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Quantum BioPharma Business Description

Traded in Other Exchanges
Address
55 University Avenue, Suite 1003, Toronto, ON, CAN, M5J 2H7
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.

Quantum BioPharma Headlines

From GuruFocus